Biopharmaceutical considerations in topical ocular drug delivery.
about
Ultrasound-enhanced delivery of antibiotics and anti-inflammatory drugs into the eye.Mini drug pump for ophthalmic use.Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery systemDevelopment of topical ophthalmic In Situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts.Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.MRI in ocular drug delivery.Effect of blinking on tear volume after instillation of midviscosity artificial tears.Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.A novel ion-exchange carrier based upon liposome-encapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride.Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis.In vitro cell culture models to study the corneal drug absorption.Ocular drug delivery system: a reference to natural polymers.A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye.Ophthalmic applications of lipid-based drug nanocarriers: an update of research and patenting activity.Topical drug delivery systems: a patent review.In vitro and ex vivo corneal penetration and absorption models.Quercetin and the ocular surface: What we know and where we are going.Nanoparticles for drug delivery to the anterior segment of the eye.In vitro pharmaceutical characterization and statistical optimization of a novel topically applied instantly-soluble solid eye drop matrix.The Effect of Diluted Penetration Enhancer in Nebulized Mist versus Liquid Drop Preparation Forms on Retrobulbar Blood Flow in Healthy Human Subjects.Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits.Effect of formulation factors on in vitro transcorneal permeation of voriconazole from aqueous drops.A novel D2-dopaminergic and alpha2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits.Mucus-Penetrating Nanosuspensions for Enhanced Delivery of Poorly Soluble Drugs to Mucosal Surfaces.Lecithin-linker microemulsion gelatin gels for extended drug delivery.Hp-β-CD-voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment.Dendrimers for Ocular Drug Delivery.Drug delivery into the eye with the use of ultrasound.Lipid emulsions as a potential delivery system for ocular use of azithromycin.Ciprofloxacin liposomes as vesicular reservoirs for ocular delivery: formulation, optimization, and in vitro characterization.Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno.An Implantable Micro-Caged Device for Direct Local Delivery of Agents.Functional nanocarrier for drug and gene delivery via local administration in mucosal tissues.Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 32 factorial design.Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.Topical administration of regorafenib eye drops: Phase I dose-escalation study in healthy volunteers.Model for Porosity Changes Occurring during Ultrasound-Enhanced Transcorneal Drug Delivery.Ocular Drug Delivery.Long-Term Subconjunctival Delivery of Brimonidine Tartrate for Glaucoma Treatment Using a Microspheres/Carrier System.
P2860
Q30441010-7C42090A-F9C6-4B81-9499-DD1DB01CA437Q33623415-AA137844-0EFA-47EA-BBDA-636B57D38543Q34493789-803A6DC8-C1F2-4286-A145-A6C48C75A162Q35184990-2603672E-48DE-4555-B94D-4FDC2E8B7ADAQ36286152-613BE0A0-1C01-426B-A10A-A6017C956C24Q36440361-682E0A95-2BAD-4612-9222-1834CBE33340Q37054230-82435EA3-7556-4A7B-8B6A-9D9165C97114Q37342780-48D1A31A-68C2-4239-8D6F-80C9E6C94617Q37573788-E94030DD-3F26-4E80-AE97-7500B4BFE909Q37684644-B1A1474D-20D4-43BC-958A-01F4E4980DB9Q37750488-6D1B7605-5715-4280-965A-EDB358C835E0Q37850457-16C31216-7541-467D-8B85-A9A58FFCF1C0Q38019052-7F55431F-14D7-42EB-BBD4-3E398B0F147FQ38196445-BD774CE6-EA37-4A6C-BE9E-882BD44E4A79Q38648168-4211441E-E180-470D-A86C-D5D02E168495Q38664367-E97C4D76-9670-4509-9476-535C0B07E003Q38695101-1CFB3800-405B-47D6-9E50-BA21F7A49DF4Q39068539-EF2D7F43-3F43-4905-8C18-854AF0193BF7Q39230212-5B254ED7-793D-426E-8CA7-C98033EB155FQ39266143-9BEB7629-E5EA-48E8-9ED6-823C3D0BA4ABQ41988607-3ADBD16D-ABFF-4115-93CF-BD4CD5DC4A80Q42036571-076D091A-C95D-4DD3-A8A1-A9A4DB4F8A70Q42125128-8C65FD1B-F2A8-4A64-8BDF-1EDB919C1566Q42166577-320D738A-7CD2-4D94-8F86-EA8A9DEF2184Q42761110-4C53A58F-C94F-4869-A3AF-8F3318A028DCQ42876118-86CFBA9B-7E25-4927-A0BD-301FFA707B44Q43463739-FE3EA234-D69B-40AC-802B-0F196CBAB891Q45073183-8180F9D1-6E63-4402-9351-6EAC9C3A42F8Q45078110-0A2CD8EE-D23B-4F9B-9927-C65B9E43CE83Q45998067-3B557F93-CDD5-4AF4-B162-BD7BD85816E1Q46220374-34F46C96-2436-4ADC-9AA3-D7A7110D3F8AQ46437932-A5501DA5-6760-4357-9C40-9DC124E36235Q47098539-B3EB260D-E163-45DD-8330-40F44E8115A5Q47316408-7FAD2D6E-7042-436A-8061-FC799D219184Q47329132-19C03DCD-67FC-45ED-884B-F99FB56518D6Q50097437-34329822-C36D-4DE3-BE9A-3FBF5CC6E62DQ50119662-7AA147CD-8FE4-47D3-BF46-B342F9AB5E1DQ50778322-0F07488F-416B-463F-86A6-B49BD6B26ECFQ51122641-17508E5A-C0C4-4618-87EC-D239E1DA9516Q51167186-99DE28E2-5DAE-4A88-8916-9BC89085A8E9
P2860
Biopharmaceutical considerations in topical ocular drug delivery.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Biopharmaceutical considerations in topical ocular drug delivery.
@ast
Biopharmaceutical considerations in topical ocular drug delivery.
@en
type
label
Biopharmaceutical considerations in topical ocular drug delivery.
@ast
Biopharmaceutical considerations in topical ocular drug delivery.
@en
prefLabel
Biopharmaceutical considerations in topical ocular drug delivery.
@ast
Biopharmaceutical considerations in topical ocular drug delivery.
@en
P2860
P1476
Biopharmaceutical considerations in topical ocular drug delivery.
@en
P2093
P2860
P304
P356
10.1046/J.1440-1681.2000.03288.X
P577
2000-07-01T00:00:00Z